Skip to main content
OpenTrials
Completed

NCT Number: NCT06267846

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Neurocrine Clinical Site, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

Participants must meet all of the following inclusion criteria:

  • Primary diagnosis of recurrent MDD or persistent MDD.
  • Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s).
  • Participants must be willing and able to comply with all study procedures and restrictions.

Key Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  • Participant is pregnant or breastfeeding or plan to become pregnant during the study.
  • Participant has an unstable medical condition or unstable chronic disease.
  • Participant has a history of neurological abnormalities.
  • Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD.
  • Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy.
  • Participant has an alcohol or substance use disorder.

Note: Other inclusion/exclusion criteria may apply

Treatment and study plan

NBI-1070770

Drug

Suspension for oral administration

Placebo

Drug

Suspension for oral administration

Primary outcomes

  1. Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5

    Time frame: Baseline, Day 5

Secondary outcomes

  1. Change in Total MADRS Score from Baseline at Postbaseline Timepoints

    Time frame: Baseline, up to Day 49

Sponsors and collaborators

Lead sponsor

Neurocrine Biosciences

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 20, 2024
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.